Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT00006721 Information provided by National Cancer Institute (NCI)
First Received: December 6, 2000 Last Updated: April 14, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
rituximab
cyclophosphamide
doxorubicin hydrochloride
prednisone
vincristine sulfate
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Doxorubicin
Iodine
Iodine-131 anti-B1 antibody
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Anti-Infective Agents, Local
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Glucocorticoids
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Tubulin Modulators
Sponsors listed in this trial
Southwest Oncology Group
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
Back to top of Main Content
